ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Prophylaxis"

  • 2019 American Transplant Congress

    Real World Data Support International Consenus Guidelines on Management of CMV after Kidney Transplantation

    A. Asberg, G. B. Kro, A. V. Reisæter, A. Hartmann, K. Midtvedt

    Oslo University Hospital - Rikshospitalet, Oslo, Norway

    *Purpose: Cytomegalovirus (CMV) naïve kidney transplant recipients (R-) transplanted with an organ from a CMV positive donor (D+) are at high risk for CMV disease.…
  • 2019 American Transplant Congress

    Pharmacokinetics of Innovative versus Generic Valganciclovir in Kidney Transplant Recipients

    I. Parra-Avila1, A. Cohen-Bucay1, J. Alberu2, G. Castañeda-Hernandez3, L. E. Morales-Buenrostro1

    1Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Ciudad de Mexico, Mexico, 2Transplant, Instituto Nacional de Ciencias Médicas y Nutrición, Ciudad de Mexico, Mexico, 3Pharmacology, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de Mexico, Mexico

    *Purpose: In kidney transplant recipients (KTR), cytomegalovirus (CMV) is a common viral infection associated with significant morbidity and mortality. In the absence of prophylaxis, CMV…
  • 2019 American Transplant Congress

    Low Incidence of Acute Renal Failure with Minimal Prophylaxis after Iodinated-Contrast TC in Ambulatory Renal Transplant Patients

    C. Jimenez1, S. Afonso1, M. O. Lopez1, M. E. Gonzalez1, M. J. Santana1, A. Santiago2, M. A. Vaca1, M. Ferreira1, R. Selgas1

    1Nephrology, Hospital Universitario La Paz, Madrid, Spain, 2Radiology, Hospital Universitario La Paz, Madrid, Spain

    *Purpose: Kidney transplant patients are at risk of contrast-induced nephropathy. CT scan with contrast is a very common imaging test. Our objective is to study…
  • 2019 American Transplant Congress

    Prolonged Fluoroquinolone Prophylaxis to Prevent BK Viremia in Kidney Transplant Recipients

    S. A. Muhsin1, S. J. Ripley2, M. L. Jacobs3, K. Safa1, D. M. Wojciechowski1

    1Nephrology Division, MGH, Boston, MA, 2Cancer Center, MGH, Boston, MA, 3Wake Forest University School of Medicine, Winston-Salem, NC

    *Purpose: Prophylaxis for kidney transplant recipients has successfully lowered early incidence of infections such as CMV. However, there are no approved agents for the prevention…
  • 2018 American Transplant Congress

    A Retrospective Review of De Novo Coccidioidomycosis among Remote Solid Organ Transplant Recipients in Arizona

    T. Zangeneh,1 J. August,1 N. Beatty,1 K. Asbury,2 L. Mi,2 J. Blair.2

    1Medicine/Division of Infectious Diseases, University of Arizona/Banner University Medical Center/Valley Fever Center for Excellence, Tucson, AZ; 2Medicine/Division of Infectious Diseases, Mayo Clinic Hospital, Phoenix, AZ.

    Background: Solid organ transplant (SOT) recipients residing in a Coccidioides-endemic region that acquire infection are at risk for complicated and protracted infection. Following transplantation, prophylaxis…
  • 2018 American Transplant Congress

    Pneumocystis jiroveci Pneumonia (PJP) in Kidney and Pancreas Transplant Recipients in the Present Era of Routine Post-Transplant Prophylaxis: Risk Factors and Outcomes

    N. Garg, M. Jorgenson, M. Birschbach, J. Descourouez, S. Parajuli, B. Astor, A. Djamali, D. Mandelbrot.

    University of Wisconsin, Madison.

    PJP after transplant (TX) is associated with substantial morbidity and mortality. In the present era of universal and routine implementation of PJP prophylaxis (PPX) during…
  • 2018 American Transplant Congress

    Impact of Pneumocystis Prophylaxis on Incidence of Treated Urinary Tract Infections Following Kidney Transplantation

    S. Sanchez, M. Brokhof, N. Kenyon, C. Varughese, N. Alvey.

    Rush University Medical Center, Chicago, IL.

    Background: Urinary tract infection (UTI) is the most common infectious complication after kidney transplantation resulting in increased morbidity and mortality. Sulfamethoxazole[mdash]trimethoprim (SMX-TMP) is commonly used…
  • 2018 American Transplant Congress

    Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients

    N. Wilson, N. Sulejmani, A. Jantz, A. Patel, B. Summers.

    Henry Ford Hospital, Detroit, MI.

    Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…
  • 2018 American Transplant Congress

    Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients

    I. Helanterä,1 F. Ortiz,2 R. Loginov,3 L. Mannonen,3 M. Lempinen,1 I. Lautenschlager.3

    1Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland; 2Nephrology, Helsinki University Hospital, Helsinki, Finland; 3Virology, Helsinki University Hospital, Helsinki, Finland.

    A. Prophylaxis has mostly replaced preemptive therapy in CMV seronegative recipients of kidneys from seropositive donors (D+/R-). Primary infections occur commonly even after six months…
  • 2018 American Transplant Congress

    Outpatient Prophylactic Valganciclovir Dose Optimization Post-Renal Transplant

    M. Spinner,1 V. Athans,1 C. Koval.2

    1Dept. of Pharmacy, Cleveland Clinic, Cleveland, OH; 2Dept. of Infectious Diseases, Cleveland Clinic, Cleveland, OH.

    Purpose: Renal function rapidly changes post-transplant requiring dose adjustment of CMV prophylaxis. We describe valganciclovir (VGCV) dosing accuracy in the outpatient setting and its associated…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences